Tolperisone, lidocaine (Tolsitol) injections 100 mg/ml + 2.5 mg/ml 1 ml – [5 ampoules]

Tolperizone hydrochloride is a myorelaxant of central action. It has membrane-stabilizing, local anesthetic effect, inhibits conduction of nerve impulses in primary afferent fibers and motor neurons, which leads to blocking of spinal mono- and polysynaptic reflexes. Probably mediates the blocking of mediator release by inhibition of calcium ions entry into synapses. Inhibits the conduction of excitation along the reticulo-spinal pathway in the brainstem.

Regardless of the effect on the central nervous system (CNS), it increases peripheral blood flow. The weak antispasmodic and antiadrenergic effects of tolperizone may play a role in the development of this effect. Lidocaine hydrochloride has local anesthetic effect and has no systemic action when dosed according to the instructions.

-symptomatic treatment of stroke-induced spasticity in adults;

-Moderate to severe myofascial pain syndrome (including muscle spasm in dorsopathies).

-Hypersensitivity to the components of the drug, including lidocaine;

-severe myasthenia gravis;

Pregnancy and breast-feeding period;

-Children and adolescents under 18 years of age.

Caution

Use in patients with renal and hepatic insufficiency. No dose adjustment is required.

Administration during pregnancy and lactation

Pregnancy

Teratogenic effect of tolperizone was not revealed in experimental studies on animals. For the reason of lack of significant clinical data tolperizone should not be used during pregnancy, except for cases when the expected benefits definitely justify the potential risk for the fetus.

Breast-feeding period

As there are no data on excretion of tolperizone with breast milk, its use during breast-feeding is contraindicated.

The preparation is given to adults intramuscularly – 100 mg (1 ml) 2 times a day or intravenously – 100 mg (1 ml) 1 time a day.